Indication
C3 glomerulopathy
5 clinical trials
3 products
Product
PegcetacoplanClinical trial
US Early Access Program for the Treatment of Patients With C3 Glomerulopathy or Primary Immune-Complex Membranoproliferative Glomerulonephritis With PegcetacoplanStatus:
Clinical trial
A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC-MPGNStatus: Active (not recruiting), Estimated PCD: 2023-02-27
Clinical trial
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Complement 3 Glomerulopathy.Status: Recruiting, Estimated PCD: 2026-03-30
Product
PlaceboProduct
iptacopanClinical trial
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisStatus: Active (not recruiting), Estimated PCD: 2027-07-01